Primary Care Physicians, physician assistants, registered nurses, nurse practitioners, and other allied healthcare professionals interested in the treatment of asthma.

• Discuss the cardinal features of inflammation and the primary role that inflammation plays in the pathophysiology of asthma.
• Explain the link between inflammation and the severity of asthma.
• Describe the potential added benefits of more direct measure of inflammation in assessing asthma control.
• Identify important therapeutic targets in inflammation of the airways.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the sponsorship of National Jewish Medical and Research Center s Office of Professional Education. National Jewish Medical and Research Center is accredited by the ACCME to provide continuing medical education for physicians.

National Jewish Medical and Research Center designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Richard J. Martin, MD, Program Chair
Chairman, Department of Medicine
Edelstein Family Chair in Pulmonary Medicine
National Jewish Medical and Research Center
Professor of Medicine National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, CO

Professor of Medicine
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, CO

Rafeul Alam, MD, PhD
Veda & Chauncey Ritter Chair in Immunology
Professor & Director, Division of Allergy & Immunology
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, CO

Barbara P. Yawn, MD, MSc
Director of Research
Olmsted Medical Center
Adjunct Professor
Department of Family Medicine and Community Health
University of Minnesota
Rochester, MN

All faculty in a position to control of the content of this activity are expected to disclose any or no significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.

KEY
± Grant Support
^ Consultant
˜ Speaker's Bureau
> Other

Rafeul Alam, MD, PhD
No significant financial interest

Ronina Covar, MD
^ AstraZeneca, Merck & Co., Inc.
± AstraZeneca, Ross Products/Abbott Laboratories

Stephen K. Frankel, MD
Has no significant financial interest to report

Richard Martin, MD
^  ± Altana, GlaxoSmithKline, Teva
^ ˜ AstraZeneca, Genentech, Merck, Novartis, sanofi-aventis, Schering-Plough
^ KaloBios, EarlySense

Harold Nelson, MD
National Jewish Medical and Research Center
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Schering Plough (Integrated Therapeutics Group)
˜ AstraZeneca, GlaxoSmithKline
± Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Sepracor, Inc., Novartis, Schering Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd., Wyeth

Richard W. Weber, MD
^ AstraZeneca, Genentech/Novartis

˜ AstraZeneca, Genentech/Novartis, GlaxoSmithKline
± Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.

Barbara Yawn, MD
± Altana, Schering-Plough

This activity is supported by a educational grant from Schering-Plough.